Share chart Novo Nordisk A/S
Extended chart
Simple chart
About Novo Nordisk A/S
Novo Nordisk A/S, медицинская компания, занимается исследованиями, разработками, производством и маркетингом фармацевтической продукции по всему миру. Он работает в двух сегментах: лечение диабета и ожирения и биофармация. Сегмент лечения диабета и ожирения предоставляет продукты в области инсулинов, GLP-1 и родственных систем доставки, пероральных противодиабетических продуктов, ожирения и других хронических заболеваний. Сегмент биофармацевтических препаратов предлагает продукты для лечения гемофилии, нарушений роста и заместительной гормональной терапии. more detailsMain settings
IPO date
1982-01-04
ISIN
US6701002056
Industry
Pharmaceuticals
Sector
Health Care
Валюта
usd
Валюта отчета
dkk
Див.доход ао
2.44
Дивиденд ао
1.14
Сайт
Grade
Underestimation
| Title | Value | Grade |
| P/S | 9.44 | 1 |
| P/BV | 19.11 | 1 |
| P/E | 27.15 | 6 |
Efficiency
| Title | Value | Grade |
| ROA | 25.89 | 8 |
| ROE | 80.78 | 10 |
| ROIC | 63.87 | 10 |
Dividends
| Title | Value | Grade |
| Dividend yield | 1.74 | 4.35 |
| DSI | 0.9286 | 9.29 |
| Average dividend growth | 30.22 | 10 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | 0.7482 | 9 |
| Debt/Ratio | 0.2207 | 10 |
| Debt/Equity | 0.7164 | 9 |
Growth impulse
| Title | Value | Grade |
| Yield Revenue, % | 128.76 | 10 |
| Yield Ebitda, % | 128.14 | 10 |
| Yield EPS, % | 1523.58 | 10 |
Dividends
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 81.05 $ | 0 $ | 0 $ | -1.51 % | 0 % | 0 % |
| Week | 75.46 $ | 75.46 $ | 81.05 $ | 5.79 % | 0 % | 0 % |
| Month | 67.35 $ | 64.37 $ | 81.05 $ | 18.53 % | 0 % | 0 % |
| Three month | 61.21 $ | 58.08 $ | 81.05 $ | 30.42 % | 0 % | 0 % |
| Half a year | 85.73 $ | 58.08 $ | 105.96 $ | -6.88 % | 0 % | 0 % |
| Year | 137.52 $ | 58.08 $ | 146.91 $ | -41.95 % | 0 % | 0 % |
| 3 years | 102.24 $ | 58.08 $ | 199.54 $ | -21.92 % | 0 % | 0 % |
| 5 years | 65.11 $ | 58.08 $ | 199.54 $ | 22.61 % | 0 % | 0 % |
| 10 years | 55.18 $ | 31.57 $ | 199.54 $ | 44.67 % | 0 % | 0 % |
| Year to date | 77.87 $ | 58.08 $ | 90.95 $ | 2.52 % | 0 % | 0 % |
Main owners
Contained in ETF
| ETF | Share, % | Profitability for 1 year, % | Commission, % |
| Fidelity Growth Opportunities ETF | 0.45018 | -7.91 | 0.38 |
| Fidelity New Millennium ETF | 0.32428 | -6.7 | 0.38 |
| 0.39 | -7.3 | 0.38 |
|---|
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
| Mr. Lars Fruergaard Jorgensen | President, CEO & Member of Management Board | 4.67M | 1966 (59 years) |
| Mr. Karsten Munk Knudsen | Executive VP, CFO & Member of the Management Board | 1.85M | 1971 (54 years) |
| Mr. Henrik Ehlers Wulff | Executive VP of Product Supply, Quality & IT and Member of the Management Board | 1.87M | 1970 (55 years) |
| Ms. Camilla Sylvest | Executive VP of Commercial Strategy & Corporate Affairs and Member of the Management Board | 1.82M | 1972 (53 years) |
| Mr. Maziar Mike Doustdar | Executive VP of International Operations & Member of the Management Board | N/A | 1970 (55 years) |
| Mr. Douglas J. Langa | Executive VP of North America Operations & Member of Management Board | N/A | 1966 (59 years) |
| Mr. Ludovic Helfgott | Executive VP, Head of Rare Disease & Member of Management Board | N/A | 1974 (51 year) |
| Dr. Martin Holst Lange | Executive VP of Development & Member of the Management Board | 1.77M | 1970 (55 years) |
| Dr. Marcus Schindler Ph.D. | EVP of Research & Early Development, Chief Scientific Officer & Member of the Management Board | 1.77M | 1966 (59 years) |
| Ms. Tania Sabroe | Executive VP of Global People & Organisation and Member of Management Board | N/A | 1977 (48 years) |
About company
Address: Denmark, Bagsvaerd, Novo Alle 1 - Open in google maps, Open in yandex maps
Website: https://www.novonordisk.com
Website: https://www.novonordisk.com
